PreCardix Professional Resources

Clinical Research

PreCardix is the result of over a decade of blood pressure research and clinical study dedicated to finding an effective, sustainable and proven natural blood pressure solution.

Two clinical studies, Marealis 13TBHM (preliminary clinical trial) and Mare-study (peer-reviewed, double-blind, placebo-controlled, multicentre clinical trial), were conducted on PreCardix between 2012 and 2015 with over two hundred and twenty male and female participants ages 30 – 75. Clinical results show that the bioactive marine peptides in PreCardix have a natural ACE inhibiting effect on the body resulting in a significant blood pressure reduction in over 89% of participants within eight weeks or less.

Highlights Mare-study:

• 1,200 mg per day of PreCardix® protein hydrolysate was found to have a statistically significant reduction in systolic and diastolic blood pressure on mild to moderate hypertensive subjects
• Angiotensin II levels were significantly reduced in the treatment group compared to baseline documenting the ACE-inhibitory effect
• 89% of clinical trial participants experienced a significant blood pressure lowering effect within 8 weeks
• 43% of clinical trial participants reduced their blood pressure by over 10mmHg in 8 weeks
• 24% of clinical trial participants reduced their blood pressure by over 15mmHg within 8 weeks

Product Monograph

FAQ